Double maintains 1 strategies that include CHRS - Coherus Oncology, Inc.
Current Value
$0.761 Year Return
Current Value
$0.761 Year Return
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
GO | -0.02% | $1.28B | -37.44% | 0.00% |
KMB | -0.03% | $42.46B | -9.68% | 3.87% |
SPTN | 0.05% | $607.94M | -4.82% | 4.85% |
O | -0.07% | $52.00B | +8.44% | 5.53% |
D | -0.08% | $46.20B | +9.63% | 4.91% |
CB | -0.10% | $113.06B | +7.27% | 1.30% |
POST | -0.12% | $6.28B | +10.46% | 0.00% |
SAFT | 0.14% | $1.16B | +2.99% | 4.58% |
UGP | -0.15% | $3.42B | -19.49% | 3.89% |
DHC | 0.15% | $890.22M | +31.32% | 1.07% |
TMUS | -0.17% | $250.92B | +24.42% | 1.48% |
FIHL | 0.20% | $1.76B | +1.25% | 1.83% |
SAVA | -0.23% | $100.00M | -89.39% | 0.00% |
NOC | -0.25% | $71.19B | +16.16% | 1.71% |
ACI | -0.26% | $12.14B | +5.82% | 2.55% |
TRV | -0.32% | $60.02B | +27.04% | 1.56% |
CARM | 0.42% | $20.99M | -51.23% | 0.00% |
LUMN | 0.49% | $4.08B | +271.96% | 0.00% |
MGPI | -0.51% | $648.36M | -58.42% | 1.55% |
AWR | -0.52% | $3.00B | +10.69% | 2.39% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
CBOE | -13.22% | $23.83B | +34.36% | 1.10% |
CME | -11.20% | $98.05B | +38.45% | 3.91% |
VSA | -11.20% | $8.84M | -14.05% | 0.00% |
VSTA | -11.06% | $350.48M | +43.28% | 0.00% |
DUK | -9.41% | $89.06B | +14.55% | 3.64% |
KR | -9.22% | $43.63B | +26.05% | 1.89% |
EXC | -7.68% | $42.77B | +21.44% | 3.67% |
T | -7.40% | $199.03B | +53.24% | 4.01% |
ED | -7.28% | $36.29B | +11.44% | 3.33% |
AEP | -6.77% | $54.06B | +15.59% | 3.62% |
MO | -6.68% | $100.21B | +32.79% | 6.87% |
AMED | -6.63% | $3.21B | +6.83% | 0.00% |
ES | -6.23% | $22.92B | +7.59% | 4.68% |
VIV | -6.06% | $17.45B | +37.09% | 0.50% |
TIMB | -6.06% | $9.31B | +34.04% | 2.66% |
IMNN | -6.04% | $20.32M | -6.54% | 0.00% |
AEE | -5.95% | $26.12B | +34.52% | 2.91% |
VZ | -5.78% | $175.69B | +3.97% | 6.46% |
PHYS | -5.33% | - | - | 0.00% |
BTI | -5.30% | $108.09B | +58.55% | 6.18% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
WSM | 46.99% | $19.73B | +0.32% | 1.48% |
XENE | 37.69% | $2.45B | -12.00% | 0.00% |
W | 37.58% | $6.30B | -5.94% | 0.00% |
RGEN | 36.45% | $6.60B | -4.44% | 0.00% |
KEYS | 35.20% | $27.56B | +17.66% | 0.00% |
DLB | 34.97% | $7.05B | -6.87% | 1.75% |
ETSY | 34.54% | $5.77B | -4.11% | 0.00% |
ZG | 33.90% | $15.93B | +38.72% | 0.00% |
Z | 33.75% | $16.31B | +37.76% | 0.00% |
TREX | 33.31% | $5.64B | -37.51% | 0.00% |
AZTA | 33.27% | $1.37B | -46.56% | 0.00% |
SITE | 33.24% | $5.24B | -10.73% | 0.00% |
TECH | 32.88% | $7.86B | -32.75% | 0.64% |
SMLR | 32.84% | $356.18M | -14.26% | 0.00% |
BRKR | 32.78% | $5.82B | -42.46% | 0.51% |
BLFS | 32.75% | $1.02B | +7.82% | 0.00% |
IMNM | 32.67% | $768.32M | -33.51% | 0.00% |
PX | 32.62% | $1.01B | +11.37% | 1.57% |
OVID | 32.53% | $21.04M | -62.44% | 0.00% |
QTWO | 32.49% | $5.54B | +53.71% | 0.00% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
TDTT | -0.05% | $2.61B | 0.18% |
SUSB | 0.07% | $979.18M | 0.12% |
SMB | 0.07% | $273.24M | 0.07% |
UTEN | 0.09% | $205.96M | 0.15% |
FXB | 0.15% | $84.47M | 0.4% |
IBDS | -0.19% | $3.10B | 0.1% |
ICSH | -0.22% | $6.12B | 0.08% |
XBIL | 0.22% | $795.25M | 0.15% |
BILZ | 0.23% | $840.74M | 0.14% |
IEF | 0.23% | $34.13B | 0.15% |
JMST | 0.23% | $4.00B | 0.18% |
ISTB | -0.27% | $4.42B | 0.06% |
STOT | -0.34% | $248.21M | 0.45% |
DFNM | -0.35% | $1.56B | 0.17% |
HYD | 0.38% | $3.29B | 0.32% |
PULS | -0.39% | $11.55B | 0.15% |
BSCR | 0.48% | $3.61B | 0.1% |
GVI | 0.49% | $3.38B | 0.2% |
FLGV | -0.51% | $995.15M | 0.09% |
USFR | -0.52% | $18.63B | 0.15% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
VIXY | -27.99% | $185.08M | 0.85% |
BTAL | -27.95% | $291.48M | 1.43% |
TAIL | -22.68% | $101.78M | 0.59% |
XONE | -16.96% | $640.90M | 0.03% |
IVOL | -14.09% | $349.05M | 1.02% |
XHLF | -13.21% | $1.72B | 0.03% |
SPTS | -13.08% | $5.74B | 0.03% |
IBMN | -11.13% | $449.19M | 0.18% |
TBLL | -9.58% | $2.22B | 0.08% |
ULST | -9.50% | $668.01M | 0.2% |
UTWO | -9.33% | $372.79M | 0.15% |
FXY | -9.01% | $853.67M | 0.4% |
VGSH | -8.34% | $22.55B | 0.03% |
IBTG | -8.33% | $1.96B | 0.07% |
CARY | -8.23% | $347.36M | 0.8% |
IBTH | -7.65% | $1.58B | 0.07% |
IGOV | -7.19% | $1.17B | 0.35% |
GBIL | -7.13% | $6.38B | 0.12% |
BILS | -7.07% | $3.91B | 0.1356% |
NEAR | -7.02% | $3.29B | 0.25% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
ARKG | 38.11% | $1.02B | 0.75% |
XBI | 38.07% | $4.66B | 0.35% |
PBE | 37.92% | $222.71M | 0.58% |
IBB | 36.42% | $5.44B | 0.45% |
IWC | 35.93% | $801.78M | 0.6% |
VBK | 35.83% | $18.40B | 0.07% |
IWO | 35.41% | $11.30B | 0.24% |
PINK | 35.39% | $131.33M | 0.5% |
ESPO | 35.34% | $370.73M | 0.56% |
GNOM | 35.13% | $43.17M | 0.5% |
PTH | 34.64% | $101.31M | 0.6% |
QQQJ | 34.42% | $604.89M | 0.15% |
KJAN | 34.23% | $284.74M | 0.79% |
XMHQ | 34.23% | $4.92B | 0.25% |
VFLO | 34.02% | $5.00B | 0.39% |
ITEQ | 33.93% | $90.97M | 0.75% |
KOMP | 33.80% | $2.59B | 0.2% |
IBUY | 33.74% | $146.65M | 0.65% |
ISCG | 33.59% | $662.94M | 0.06% |
KJUL | 33.56% | $117.87M | 0.79% |
Yahoo
We came across a bullish thesis on Coherus BioSciences, Inc. (CHRS) on Steve Wagner’s Substack. In this article, we will summarize the bulls’ thesis on CHRS. Coherus BioSciences, Inc. (CHRS)’s share was trading at $0.77 as of 30th May. CHRS’s trailing P/E was 1.77 according to Yahoo Finance. Coherus BioSciences (CHRS), long overlooked by Wall Street, is […]
Yahoo
REDWOOD CITY, Calif., May 30, 2025 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (Coherus Oncology, Nasdaq: CHRS), a commercial-stage innovative oncology company, formerly named Coherus BioSciences Inc., announced its name change today to better align with its exclusive focus on proprietary innovative immuno-oncology medicines. “The field of cancer immunotherapy has been reinvigorated by the promise and power of combination therapies. Coherus Oncology has the expertise and pipeline to become a sign
Finnhub
Coherus BioSciences Inc: * COHERUS COMPLETES STRATEGIC TRANSFORMATION TO COHERUSONCOLOGY,FOCUSING EXCLUSIVELY ON INNOVATIVE CANCER THERAPEUTICSSource text:Further company coverage: ...
Finnhub
Coherus BioSciences, Inc. announced a clinical collaboration with STORM Therapeutics Ltd. to evaluate STC-15, a METTL3 inhibitor, in combination with LOQTORZI , a next-generation PD-1 inhibitor, in a...
Yahoo
– First patient dosed in a Phase 1b/2 study evaluating STC-15, a METTL3 inhibitor, in combination with LOQTORZI, a next-generation PD-1 inhibitor –REDWOOD CITY, Calif., May 27, 2025 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS), today announced a clinical collaboration with STORM Therapeutics, Ltd. (“STORM”) to evaluate STC-15, a METTL3 inhibitor, in combination with LOQTORZI (toripalimab-tpzi), a next-generation PD-1 inhibitor, in a Phase 1b/2 study for the treatment o
Yahoo
Coherus BioSciences ( NASDAQ:CHRS ) First Quarter 2025 Results Key Financial Results Revenue: US$7.60m (down 90% from...